Tocilizumab, a monoclonal antibody against the IL-6R, was the first biologic agent to be largely evaluated in COVID-19 patients, also based on precipitous inclusion in the Chinese guidelines for the treatment of COVID-19 patients at the beginning of the pandemic (Di Giambenedetto et al., 2020). The gene discussed is IL6R; the disease is COVID-19.